ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Coronary Artery Disease: Optimal Lipoprotein(a) for Survival-Lower Is Better? A Large Cohort With 43,647 Patients

Liu, Jin; Liu, Liwei; Wang, Bo; Chen, Shiqun; Liu, Buyun; Liang, Jingjing; Huang, Haozhang; Li, Qiang; Lun, Zhubin; Ying, Ming; Chen, Guanzhong; Huang, Zhidong; Xu, Danyuan; Yan, Xiaoming; Zhu, Tingting; Tadesse, Girmaw Abebe; Tan, Ning; Chen, Jiyan; Liu, Yong*广东省人民医院; 广东省心血管病研究所; 南方医科大学; y
Frontiers in Cardiovascular Medicine2021-8-31DOI: 10.3389/fcvm.2021.670859
2被引11阅读
引用收藏
分享

摘要

Background: A high level of lipoprotein(a) can lead to a high risk of cardiovascular events or mortality. However, the association of moderately elevated lipoprotein(a) levels (>= 15 mg/dL) with long-term prognosis among patients with coronary artery disease (CAD) is still uncertain. Hence, we aim to systematically analyzed the relevance of baseline plasma lipoprotein(a) levels to long-term mortality in a large cohort of CAD patients. @@@ Methods: We obtained data from 43,647 patients who were diagnosed with CAD and had follow-up information from January 2007 to December 2018. The patients were divided into two groups (< 15 and >= 15 mg/dL). The primary endpoint was long-term all-cause death. Kaplan-Meier curve analysis and Cox proportional hazards models were used to investigate the association between moderately elevated baseline lipoprotein(a) levels (>= 15 mg/dL) and long-term all-cause mortality. @@@ Results: During a median follow-up of 5.04 years, 3,941 (18.1%) patients died. We observed a linear association between lipoprotein(a) levels and long-term all-cause mortality. Compared with lipoprotein(a) concentrations < 15 mg/dL, lipoprotein(a) >= 15 mg/dL was associated with a significantly higher risk of all-cause mortality [adjusted hazard ratio (aHR) 1.10, 95%CI: 1.04-1.16, P-values = 0.001). Similar results were found for the subgroup analysis of non-acute myocardial infarction, non-percutaneous coronary intervention, chronic heart failure, diabetes mellitus, or non-chronic kidney diseases. @@@ Conclusion: Moderately elevated baseline plasma lipoprotein(a) levels (>= 15 mg/dL) are significantly associated with higher all-cause mortality in patients with CAD. Our finding provides a rationale for testing the lipoprotein(a)-reducing hypothesis with lower targets (even < 15 mg/dL) in CAD outcome trials.

学科与关键词

关键词
coronary artery diseasebaseline lipoprotein(a)long-term all-cause mortalitypercutaneous coronary interventioncoronary angiography
相关
加载中…
  • Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients
    Yao, Younan; Liu, Jin; Wang, Bo; Zhou, Ziyou; Lu, Xiaozhao; Huang, Zhidong; Deng, Jingru; Yang, Yongquan; Tan, Ning; Chen, Shiqun*; Chen, Jiyan*; Liu, Yong*Frontiers in Cardiovascular Medicine, 2022, 8: 817442.被引 1
  • Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study
    Huang, Zhidong; Yang, Yanfang; Lu, Jin; Liang, Jingjing; He, Yibo; Yu, Yaren; Huang, Haozhang; Li, Qiang; Wang, Bo; Li, Shanggang; Yan, Zelin; Xu, Danyuan; Liu, Yong; Chen, Kaihong; Huang, Zhigang; Ni, Jindong; Liu, Jin*; Chen, Liling*; Chen, Shiqun*Frontiers in Cardiovascular Medicine, 2021, 8: 747120.被引 3
  • Association of high-sensitivity C-reactive protein and long-term mortality may differ from lipoprotein(a) levels among patients undergoing coronary angiography
    Guo, Z.; Lei, L.; Ying, M.; Wang, B.; Liu, J.; Liu, L.; He, Y.; Sun, G.; Chen, S.; Liu, B.; Chen, G.; Chen, J.; Liu, Y.European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 2020-08-29 To 2020.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Cardiovascular Medicine
发表日期
2021-08-31
卷期
第 8 卷
页码
670859
DOI
10.3389/fcvm.2021.670859
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Beijing Lisheng Cardiovascular Health Foundation; Guangdong Provincial People's Hospital Foundation [LHJJ20141751]; Natural Science Foundation of Guangdong Province General Project [2020A1515010940]; National Science Foundation of China [81670339, 81970311]

作者

  • L

    Liu, Jin (第一作者)

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Liu, Liwei

    guangdong cardiovasc inst · guangdong prov peoples hosp

查看全部 19 位作者收起作者
  • W

    Wang, Bo

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • C

    Chen, Shiqun

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Liu, Buyun

  • L

    Liang, Jingjing

    2 · southern med univ

  • H

    Huang, Haozhang

    2 · southern med univ

  • L

    Li, Qiang

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Lun, Zhubin

  • Y

    Ying, Ming

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • C

    Chen, Guanzhong

    guangdong prov peoples hosp

  • H

    Huang, Zhidong

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • X

    Xu, Danyuan

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • Y

    Yan, Xiaoming

    guangdong prov peoples hosp

  • Z

    Zhu, Tingting

  • T

    Tadesse, Girmaw Abebe

  • T

    Tan, Ning

    guangdong cardiovasc inst · guangdong prov peoples hosp · 2 · southern med univ

  • C

    Chen, Jiyan

    guangdong prov peoples hosp · guangdong cardiovasc inst · 2 · southern med univ

  • L

    Liu, Yong (通讯)

    guangdong prov peoples hosp · guangdong cardiovasc inst · 2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417